Skip to main content

Adicet Bio to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation Conference

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Guggenheim 2nd Annual Healthcare Innovation Conference being held from November 10-12, 2025 in Boston.

Details of the event are as follows:

Date: Tuesday, November 11, 2025

Time: 3:00 p.m. ET

The live audio webcast can be accessed on the Investors section of Adicet Bio’s website at http://www.adicetbio.com. An archived replay will be available for 30 days following the presentation.

About Adicet Bio, Inc.

Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at https://www.adicetbio.com.

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  232.89
-1.80 (-0.77%)
AAPL  270.10
-2.31 (-0.85%)
AMD  247.50
+0.69 (0.28%)
BAC  52.27
-0.34 (-0.65%)
GOOG  293.22
+16.24 (5.86%)
META  609.82
+0.36 (0.06%)
MSFT  509.10
-1.08 (-0.21%)
NVDA  188.27
-1.90 (-1.00%)
ORCL  221.25
-1.60 (-0.72%)
TSLA  416.04
+11.69 (2.89%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.